Resmed Inc Drc Stock Book Value Per Share
| RSMDFDelisted Stock | USD 17.70 0.00 0.00% |
Resmed Inc DRC fundamentals help investors to digest information that contributes to Resmed's financial success or failures. It also enables traders to predict the movement of Resmed Pink Sheet. The fundamental analysis module provides a way to measure Resmed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Resmed pink sheet.
Resmed |
Resmed Inc DRC Company Book Value Per Share Analysis
Resmed's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Resmed Book Value Per Share | 6.36 X |
Most of Resmed's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Resmed Inc DRC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Resmed Inc DRC is about 6.3618 times. This is 474.22% lower than that of the Healthcare sector and 49.67% lower than that of the Medical Instruments & Supplies industry. The book value per share for all United States stocks is 99.67% higher than that of the company.
Resmed Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Resmed's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Resmed could also be used in its relative valuation, which is a method of valuing Resmed by comparing valuation metrics of similar companies.Resmed is currently under evaluation in book value per share category among its peers.
Resmed Fundamentals
| Return On Equity | 0.24 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 33.08 B | |||
| Shares Outstanding | 1.47 B | |||
| Shares Owned By Institutions | 7.93 % | |||
| Price To Earning | 28.58 X | |||
| Price To Book | 9.54 X | |||
| Price To Sales | 9.04 X | |||
| Revenue | 3.58 B | |||
| Gross Profit | 2.06 B | |||
| EBITDA | 1.18 B | |||
| Net Income | 779.44 M | |||
| Cash And Equivalents | 273.71 M | |||
| Cash Per Share | 0.47 X | |||
| Total Debt | 765.33 M | |||
| Debt To Equity | 0.27 % | |||
| Current Ratio | 2.80 X | |||
| Book Value Per Share | 6.36 X | |||
| Cash Flow From Operations | 351.15 M | |||
| Earnings Per Share | 0.55 X | |||
| Price To Earnings To Growth | 1.76 X | |||
| Target Price | 11.49 | |||
| Number Of Employees | 8.16 K | |||
| Beta | 0.47 | |||
| Market Capitalization | 34.16 B | |||
| Total Asset | 5.1 M | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 5.1 M | |||
| Last Dividend Paid | 1.72 |
About Resmed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Resmed Inc DRC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Resmed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Resmed Inc DRC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Resmed Pink Sheet
If you are still planning to invest in Resmed Inc DRC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Resmed's history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |